GlobeNewswire 12/6/2017 Immuron to Present at RedChip’s Global Online Growth Conference
GlobeNewswire 11/22/2017 Van Leeuwenhoeck Institute Updates Immuron Research Coverage
GlobeNewswire 11/15/2017 Immuron Granted US Patent for NASH Treatment
GlobeNewswire 11/9/2017 Immuron Successfully Completes NASH Phase II Clinical Study Milestone
GlobeNewswire 11/8/2017 Travelan Experiences Strong Q1 FY2018 Sales Growth
GlobeNewswire 10/17/2017 Immuron Ltd. Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. ...
GlobeNewswire 9/19/2017 Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Dis...
GlobeNewswire 8/15/2017 Immuron Commences US Non-Deal Institutional Investor Roadshow
GlobeNewswire 8/9/2017 Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
GlobeNewswire 7/10/2017 NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety a...
GlobeNewswire 6/8/2017 Immuron Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing – Raising US $6.1 ...
GlobeNewswire 4/18/2017 Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
GlobeNewswire 2/20/2017 Immuron Completes Phase II NASH Clinical Trial Recruitment
GlobeNewswire 1/19/2017 Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University
GlobeNewswire 1/18/2017 European/US Analyst: Immuron Moving to Forefront in NASH
GlobeNewswire 1/6/2017 NASH Transactions by JNJ, BMS and Novartis, Highlight Continued Appetite for NASH Assets
GlobeNewswire 12/22/2016 Enjoy Your Holiday Travel and Protect Yourself from Food-Borne Illness with Travelan
GlobeNewswire 12/22/2016 Immuron Files F-1 with the SEC
GlobeNewswire 11/29/2016 Immuron Receives $1.59M R&D Tax Concession Refund
GlobeNewswire 11/21/2016 Protect Yourself from Contaminated Food During the 2016 Holiday Travel Season with Travelan